Hemlibra

Hemlibra (emicizumab) is a medication used to prevent bleeding episodes in people with hemophilia A, a genetic disorder where blood doesn't clot properly due to missing or defective clotting factors. Hemlibra works by mimicking a part of the clotting process, helping blood to clot more effectively. It's administered as a weekly injection, providing a consistent level of protection. Hemlibra has transformed hemophilia management by reducing bleeding risks and the need for frequent infusions of traditional clotting factor treatments, improving quality of life for many patients.